Connect with us

News

‘Historic moment’ as first South African medical cannabis flower arrives in UK

Products will be available immediately for UK patients

Published

on

CBD in dropper
The first ever import of South African-grown medical cannabis flower has arrived in the UK

The first ever import of South African-grown medical cannabis flower has arrived in the UK, in a “historic” moment for the sector.

South African cannabis producer, MedCan is behind the first import of high-THC medical cannabis flower, grown in Johannesburg, to UK soil.

Its first product, Isando – a high THC flower containing 16.1 percent THC, 0.05 percent CBD and 0.96 percent CBG – will now be available to UK patients, through Rokshaw Laboratories. 

The flowers are said to have a rich terpene profile, with a very high concentration of Limonene giving them an intense aroma of citrus and tropical fruit. 

Due to the growing techniques used, the flowers have not been irradiated and therefore its terpenes remain intact.

MedCan, which began cultivating  in 2020, is one of the only GMP certified and fully licensed indoor cannabis cultivation facilities in South Africa.

Its commitment to the environment means the company recycles all of its water and plastic on site and no synthetic or inorganic pesticides or chemicals are used in the growing process. 

After every harvest the company also donates its grow medium to local initiative, Eco Therapist – which teaches members of the community to grow their own produce – to use as compost.

Micaël Zollmann, founder and CEO of MedCan, commented: ‘We are so excited that our product is now available in the UK. 

“At MedCan, we are passionate about cultivating a high-quality medical cannabis flower that can be accessed by those who will benefit most. 

“Our flower meets the strictest testing requirements, has a rich flavour profile, and will hopefully be well received by the patients and clinicians alike.”

MedCan is working with Maple Tree cannabis consultancy firm and Rokshaw Laboratories to bring its products to the UK.

Professor Mike Barnes, director of Maple Tree Consultants, described it as a “historic moment” for the UK sector.

“The UK sees a first of its kind import into the UK from South Africa which is a historic moment for the medical cannabis sector in the UK,” he said.

“The UK has an ever-expanding medical cannabis sector which requires good quality products with a secure supply chain. We are delighted to support MedCan with this import and are excited to see patients and clinicians have more choices to help with their symptoms.”

To place an order for Isando flower contact: orders@cbpmaccess.co.uk. Clinics and dispensaries can send orders on behalf of the patient, or the patient can send a request directly to Rokshaw.

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@handwmedia.co.uk / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.